CN114606270B - 一种Mia3条件性基因敲除小鼠模型的构建方法 - Google Patents
一种Mia3条件性基因敲除小鼠模型的构建方法 Download PDFInfo
- Publication number
- CN114606270B CN114606270B CN202210507660.3A CN202210507660A CN114606270B CN 114606270 B CN114606270 B CN 114606270B CN 202210507660 A CN202210507660 A CN 202210507660A CN 114606270 B CN114606270 B CN 114606270B
- Authority
- CN
- China
- Prior art keywords
- mouse
- sgrna
- seq
- mia3
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010172 mouse model Methods 0.000 title claims abstract description 13
- 238000010276 construction Methods 0.000 title description 8
- 238000003209 gene knockout Methods 0.000 title description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 35
- 108091033409 CRISPR Proteins 0.000 claims abstract description 16
- 238000011813 knockout mouse model Methods 0.000 claims abstract description 11
- 238000013518 transcription Methods 0.000 claims abstract description 11
- 230000035897 transcription Effects 0.000 claims abstract description 11
- 238000005516 engineering process Methods 0.000 claims abstract description 10
- 230000008685 targeting Effects 0.000 claims abstract description 9
- 235000013601 eggs Nutrition 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000013598 vector Substances 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 241001529936 Murinae Species 0.000 claims abstract description 3
- 238000012216 screening Methods 0.000 claims description 6
- 101100536803 Mus musculus Mia3 gene Proteins 0.000 claims description 5
- 238000009395 breeding Methods 0.000 claims description 4
- 230000001488 breeding effect Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000003205 genotyping method Methods 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 3
- 241000581650 Ivesia Species 0.000 claims description 2
- 210000000805 cytoplasm Anatomy 0.000 claims description 2
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108010051219 Cre recombinase Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 206010013883 Dwarfism Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 208000000088 Enchondromatosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001417092 Macrouridae Species 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 208000026616 Ollier disease Diseases 0.000 description 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000004906 unfolded protein response Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/124—Animal traits, i.e. production traits, including athletic performance or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及一种使用CRISPR/Cas9技术构建Mia3基因条件性敲除小鼠模型的方法，其包括：1、设计针对鼠源Mia3基因Exon2‑Exon7的sgRNA，2、利用体外转录技术获得上述sgRNA，3、将打靶载体、上述sgRNA、Cas9蛋白共注射或共电转至小鼠受精卵等步骤。与传统ES打靶小鼠模型相比，本发明首次构建的Mia3基因条件性敲除小鼠模型具有高效、快捷、简便、成本便宜等特点，且可以通过Cre来调控基因在特定的组织或特定时间进行表达。
Description
技术领域
本发明属于基因工程领域，具体涉及一种Mia3条件性基因敲除小鼠模型的构建方法及其应用。
背景技术
CRISPR/Cas9技术是通过设计特异性sgRNA实现特异性的DNA识别，并且在靶向位置完成切割，再通过细胞本身的DNA修复机制，完成断裂处的修复，从而实现目标基因的“编辑”。而随着CRISPR/Cas9技术的发展和研究的深入，其被广泛应用于构建转基因的模式动物（主要为基因编辑小鼠），从而为临床前提供动物层面治疗的基础研究。
人类疾病的发病机制研究和筛选有效的治疗药物均需要进行大量临床前试验。由于直接利用人细胞及组织进行临床前相关研究受到伦理方面的限制，动物模型就成为人类生物学研究的替代选择。小鼠具有体积小、易维持与操作、繁殖周期短、与人在基因组和生理学等特征方面相似，以及已经有相应成熟的基因修饰技术等优势，因此成为广泛应用的哺乳动物模式生物系统。但由于小鼠生理特征与人存在较多差异，利用动物模型得到的实验结果有时不能适用到人体上。然而利用基因修饰或细胞与组织移植的方法，将人类基因或细胞组织“放置”在小鼠模型上所制备的人源化小鼠模型（即带有人类功能性基因、人类细胞或组织的小鼠模型），极大程度上模拟人类基因或细胞组织的相关活动，大大提高了这类小鼠模型作为模拟某些人类疾病的有效性。
Mia3编码黑色素瘤抑制蛋白3，是一种进化保守的内质网常驻跨膜蛋白。有研究表明，Mia3敲除显示软骨发育不良，导致胎儿矮化、外周水肿和围产期致死。缺乏Mia3的小鼠对于从软骨细胞，成纤维细胞，内皮细胞和壁画细胞中分泌许多胶原蛋白（包括胶原蛋白I，II，III，IV，VII和IX）是有缺陷的。这些细胞类型的胶原沉积是异常的，并且细胞外基质组成受到损害。这些变化与胶原蛋白的细胞内积累和强烈的未折叠蛋白质反应的诱导有关，主要是在发育中的骨骼内。软骨细胞成熟和骨矿化在Mia3-null胚胎中受到严重损害，导致侏儒症和新生儿致死。因此，Mia3在蛋白质分泌中的作用比以前意识到的要广泛得多，实际上它可能是高等生物体中所有胶原蛋白分子有效分泌所必需的。因此开发一种Mia3 Cas9-CKO小鼠模型能够用于评价与Mia3基因缺失相关的各类研究。
条件性基因敲除（CKO）是通过把两个LoxP位点插入到目的基因的一个或几个重要外显子的两端以制备出有两个floxed小鼠。该floxed小鼠在与表达Cre重组酶小鼠杂交之前，该基因表达正常；当floxed小鼠与组织特异性表达Cre酶的小鼠进行杂交后，可实现在特定的组织或细胞中敲除该基因，而在其它组织或细胞中该基因表达正常。
Mia3 Cas9-CKO小鼠是利用基因修饰的方法，在小鼠的Mia3基因上的特定位点插入LoxP，将flox小鼠与表达Cre重组酶的小鼠交配，利用Cre-LoxP系统获得Mia3基因条件性敲除小鼠，同时通过Cre诱导可以实现在特定的组织或者特定时间对Mia3基因的敲除。
目前暂未检索到采用CRISPR/Cas9技术构建Mia3基因条件性敲除小鼠的相关报道。
发明内容
为解决上述技术问题，本发明包括以下几个方面：
本发明的第一方面提供一种Mia3基因条件性敲除小鼠模型构建方法，该方法包括如下步骤：
（1）设计针对鼠源Mia3基因Exon2-Exon7的sgRNA；
（2）利用体外转录技术获得上述sgRNA；
（3）将打靶载体、步骤（2）获得的sgRNA、Cas9蛋白共注射或共电转至小鼠受精卵细胞质或细胞核中，并将该受精卵移植至假孕小鼠，对假孕生仔鼠进行基因型鉴定，筛选成功插入正确人源片段的阳性F0小鼠；
（4）F0小鼠与背景鼠配繁获得F1小鼠，对F1代鼠尾进行基因鉴定，筛选出Mia3基因条件性敲除小鼠模型。
优选的，所述步骤（1）中两端sgRNA识别位点分别位于小鼠Mia3基因的第二个外显子之前和第七个外显子之后。
优选的，所述步骤（1）中sgRNA的基因序列为SEQ ID NO.1、SEQ ID NO.2、SEQ IDNO.3和SEQ ID NO.4中的一个或多个。
更优选的，所述步骤（1）中sgRNA的基因序列为SEQ ID NO.1和SEQ ID NO.2。
优选的，所述步骤（2）中以sgRNA-F、sgRNA-R为引物对，puc57-sgRNA质粒为模板进行PCR，PCR产物纯化制备sgRNA转录模板，并经过体外转录得到sgRNA。
优选的，所述步骤（2）中的引物对选自SEQ ID NO.5和SEQ ID NO.6，SEQ ID NO.7和SEQ ID NO.8，SEQ ID NO.9和SEQ ID NO.10，SEQ ID NO.11和SEQ ID NO.12所示序列对中一对或多对。
更优选的，所述步骤（2）中的引物对如SEQ ID NO.5和SEQ ID NO.6，以及SEQ IDNO.7和SEQ ID NO.8所示。
优选的，所述步骤（2）中的PCR反应体系如下：
优选的，所述步骤（2）中的PCR反应条件如下：
优选的，所述步骤（3）中提供受精卵的小鼠和假孕小鼠的品系为C57BL/6J。
优选的，所述步骤（3）中F0小鼠基因型鉴定使用的5’端鉴定引物如SEQ ID NO.13和SEQ ID NO.14所示，3’端鉴定引物如SEQ ID NO.15和SEQ ID NO.16所示。
优选的，所述步骤（3）中F0小鼠基因型鉴定使用的PCR反应条件如下：
优选的，所述步骤（3）中F0小鼠基因型鉴定使用的PCR反应体系如下：
本发明的第二方面提供模型构建方法得到的小鼠在研究Mia3基因相关功能和作用机制中的应用。
优选的，所述应用是非诊断和非治疗目的的。
本发明的第三方面提供上述构建方法得到的小鼠在筛选用于治疗与Mia3基因相关疾病的药物中的应用。
优选的，所述应用是非诊断和非治疗目的的。
优选的，所述疾病为心血管疾病、癌症中的一种或多种。
本发明产生的有益效果：
与传统ES打靶小鼠模型相比，本发明的Mia3基因条件性敲除小鼠模型具有高效、快捷、简便、成本便宜等特点，且CKO模型可以通过Cre来调控基因在特定的组织或特定时间进行表达，可以满足小鼠模型在不同研究方向的需求，同时节省了时间及成本。
附图说明
图1为本发明F0代小鼠Mia3-CKO 5端、3端与野生型鉴定电泳图（DNA Marker条带：600bp\500bp\400bp\300bp\200bp\100bp）；
图2为本发明F1代小鼠Mia3-CKO 5端、3端与野生型鉴定电泳图（N为空白对照，B6为阴性对照基因组DNA，DNA Marker条带：600bp\500bp\400bp\300bp\200bp\100bp）；
图3为本发明小鼠PTDSS2-CKO 5端、3端与野生型鉴定电泳图中DNA Marker条带示意图。
具体实施方式
实施例1、Mia3基因条件性敲除小鼠模型的构建
本实施例使用CRISPR Cas9技术对小鼠Mia3基因进行基因修饰，基因稳定遗传的小鼠与表达Cre重组酶的小鼠交配后，flox小鼠被敲除，敲除该区域将导致蛋白质功能被破坏。如无特别说明，本实施例采用的小鼠均为C57BL/6J品系小鼠。
1、确定条件性敲除区域及序列
根据Mia3基因的结构，将Mia3-202转录本序列的Exon2至Exon7部分作为敲除区域，该区域包含3557bp编码序列。打靶载体的序列如下所示，其中具有下划线的大写字母对应Loxp位点。Loxp 1插入第二外显子（Exon 2）的上游，Loxp 2插入第七外显子（Exon 7）的下游。
其中，Loxp1的插入位置如下所示：
AGCCACAAATGAAACTGGCAGTGTTTACTGCCGCAAAGAAACAGTTGCAGCCACTTACAGGCAGTGCCTGTTAGTGGTTAGCTCAGGTTTAATTGACCCCATTTGTCACGTCCTGCACGACTTAAGGGATCCAGATCTGGGCCCACAATAACTTCGTATAGCATACATTATACGAAGTTATATGTTCTTGCGCAAGGTCAGTTGGTTGGGGATTCCTGGGCGATCTTCCTGGCTCCCTGTTATCCCCACAGTTAGCTATGTTTAAACCAGTCAGCACCTGCACCTGCATTTACACATCCACAAAC。
Loxp2的插入位置如下所示：
TACAGATTATATGGTGTCCAAAGACACATTATTACATTTTCATTCTGTTTTTTCTGAATACAATTTGTGTTTCAGATATACACACTCACCTCTGGAACCTATCGCATTGTCTGAGTACGTGATAACTTCGTATAGCATACATTA TACGAAGTTATGGGCCAACAGAATTCGATATCCTGCAGGGACTAACAGAAGAACGCGTTGTGTGGTCTTTTCCCTAAGATACCTTCCTTGGTTTTGCTTCTGCCAACTTACCTATTCTTGTTAATTTGGGTGAAATGGGACAAGGCTATGGCATTAGAGAAA。
2、确定用于模型制备的sgRNA序列
根据据敲除区域确定sgRNA大概区域，针对目的片段选取脱靶率最低几组序列作为待选sgRNA（见下表1）。设计并合成识别5’端靶位点和3’端靶位点，并构建sgRNA表达载体。两端sgRNA识别位点分别位于小鼠Mia3基因的第二个外显子之前和第七个外显子之后，各sgRNA在Mia3上的靶位点序列（SEQ ID NO.1至SEQ ID NO.4）如下：
表1 sgRNA序列信息
sgRNA转录制备方法：以PrimerStar或PrimerStar Max体系（表2），sgRNA-F、sgRNA-R为引物，测序正确的puc57-sgRNA质粒为模板进行PCR（反应条件见表3），PCR产物进行纯化，制备sgRNA转录制备模板。使用T7-ShortScript体外转录试剂盒（AM1354）进行sgRNA的转录。
sgRNA筛选：分别将4个sgRNA与Cas9蛋白进行孵育后，将混合液注射至0.5天的受精卵中，培养至囊胚阶段后，进行小鼠Mia3基因的KO阳性率的鉴定，以此筛选切割活性高的sgRNA。
表2 sgRNA的PCR扩增体系
表3 sgRNA的PCR反应条件
sgRNA切割鉴定方法：对收集的囊胚进行巢式PCR扩增，PCR扩增引物序列见表4，将扩增条带进行二代测序，与wt条带比对，统计发生突变的概率，切割效率的鉴定结果见表5。
表4 sgRNA的PCR扩增引物序列
表5 sgRNA切割效率
3、打靶载体构建
Loxp1、Loxp2打靶载体的序列由通用生物（安徽）股份有限公司合成。
4、移植注射获得阳性鼠
将打靶载体、目的sgRNA（wJS05987-Mia3-5S1和wJS05987-Mia3-3S1）、Cas9蛋白注射到受精卵，移植至假孕小鼠。对假孕鼠生的后代（JS05987 5#-8#）进行基因型鉴定，鉴定引物信息见表6，PCR鉴定反应体系和反应条件见表7和表8，筛选成功插入正确人源片段的阳性鼠F0小鼠，F0鉴定结果如图1所示。从对照Marker条带（图3）大小对照来看，5端408bp为正确插入，3端434bp为正确插入，两端同时插入为阳性F0，图1中6#为阳性F0，将6#小鼠继续配繁。
表6 鉴定引物信息
表7 PCR鉴定反应体系
表8 PCR鉴定反应条件
阳性F0小鼠6#与背景鼠配繁获得F1，对F1代鼠尾进行基因鉴定，F1代小鼠（24#、26#、27#、28#、30#）的PCR实验结果如图2所示，从对照Marker条带可以看出，5端出现408bp条带为正确插入，303bp为WT，3端434bp为正确插入，328bp为WT，因此F1代小鼠24#、26#、27#、28#、30#皆为阳性小鼠，获得的阳性F1代小鼠即为本发明构建的Mia3基因条件性敲除小鼠模型。F1大量扩繁后进行互配，获得纯合子。
以上所述的具体实施方式，对本发明的目的、技术方案和有益效果进行了进一步详细说明，所应理解的是，以上所述仅为本发明的具体实施方式而已，并不用于限定本发明的保护范围，凡在本发明的精神和原则之内，所做的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
序列表
<110> 广东药康生物科技有限公司
<120> 一种Mia3条件性基因敲除小鼠模型的构建方法
<160> 16
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
ctcaggttta attgacccct tgg 23
<210> 2
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
cacactcacc tctggaacct tgg 23
<210> 3
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
atcgcccagg aatccccaag ggg 23
<210> 4
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 4
gtatcttagg gaaaagacca agg 23
<210> 5
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
atagtcaggt ttaattgacc cct 23
<210> 6
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 6
aaacaggggt caattaaacc tga 23
<210> 7
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
atagacactc acctctggaa cct 23
<210> 8
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
aaacaggttc cagaggtgag tgt 23
<210> 9
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
atagtcgccc aggaatcccc aag 23
<210> 10
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
aaaccttggg gattcctggg cga 23
<210> 11
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
atagtatctt agggaaaaga cca 23
<210> 12
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
aaactggtct tttccctaag ata 23
<210> 13
<211> 26
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
ttaactcatc cagacacagt gcagag 26
<210> 14
<211> 24
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 14
tttcctctct gatcttctag cccg 24
<210> 15
<211> 24
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 15
taaagccatc tcccaagcct tagc 24
<210> 16
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 16
cttccaacac aggggaatga atg 23
Claims (3)
1.一种Mia3基因条件性敲除小鼠模型构建方法，其特征在于，该方法包括如下步骤：
（1）设计针对鼠源Mia3基因Exon2-Exon7的sgRNA；
（2）利用体外转录技术获得上述sgRNA；
（3）将打靶载体、步骤（2）获得的sgRNA、Cas9蛋白共注射或共电转至小鼠受精卵细胞质或细胞核中，并将该受精卵移植至假孕小鼠，对假孕生仔鼠进行基因型鉴定，筛选成功插入正确人源片段的阳性F0小鼠；
（4）F0小鼠与背景鼠配繁获得F1小鼠，对F1代鼠尾进行基因鉴定，筛选出Mia3基因条件性敲除小鼠模型；
所述步骤（1）中两端sgRNA识别位点分别位于小鼠Mia3基因的第二个外显子之前和第七个外显子之后；
所述步骤（1）中sgRNA的基因序列为SEQ ID NO.1和SEQ ID NO.2。
2.根据权利要求1所述的小鼠模型构建方法，其特征在于，所述步骤（2）中以sgRNA-F、sgRNA-R为引物对，puc57-sgRNA质粒为模板进行PCR，PCR产物纯化制备sgRNA转录模板，并经过体外转录得到sgRNA；所述步骤（2）中的引物对如SEQ ID NO.5和SEQ ID NO.6，以及SEQID NO.7和SEQ ID NO.8所示。
3.根据权利要求1所述的小鼠模型构建方法，其特征在于，所述步骤（3）中F0小鼠基因型鉴定使用的5’端鉴定引物如SEQ ID NO.13和SEQ ID NO.14所示，3’端鉴定引物如SEQ IDNO.15和SEQ ID NO.16所示。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210507660.3A CN114606270B (zh) | 2022-05-11 | 2022-05-11 | 一种Mia3条件性基因敲除小鼠模型的构建方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210507660.3A CN114606270B (zh) | 2022-05-11 | 2022-05-11 | 一种Mia3条件性基因敲除小鼠模型的构建方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114606270A CN114606270A (zh) | 2022-06-10 |
| CN114606270B true CN114606270B (zh) | 2022-07-29 |
Family
ID=81870468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210507660.3A Active CN114606270B (zh) | 2022-05-11 | 2022-05-11 | 一种Mia3条件性基因敲除小鼠模型的构建方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114606270B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109266680A (zh) * | 2018-10-17 | 2019-01-25 | 江苏集萃药康生物科技有限公司 | 一种应用Cas9技术制备CKO/KI动物模型的方法 |
| CN109777837A (zh) * | 2018-12-26 | 2019-05-21 | 首都医科大学 | 一种利用CRISPR/Cas9系统构建致死基因全身性敲除小鼠模型的方法 |
| CN111961685A (zh) * | 2020-08-18 | 2020-11-20 | 江西中医药大学 | CRISPR Cas9条件性基因敲除鼠、建立方法 |
| CN113373178A (zh) * | 2021-08-13 | 2021-09-10 | 上海南方模式生物科技股份有限公司 | 一种tlr8基因人源化动物模型的构建方法及应用 |
| CN114107382A (zh) * | 2021-11-16 | 2022-03-01 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | G3bp1条件性基因敲除小鼠模型 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7160694B2 (en) * | 1999-06-14 | 2007-01-09 | Millennium Pharmaceuticals, Inc. | Nucleic acids encoding TANGO405 and functional fragments and uses thereof |
-
2022
- 2022-05-11 CN CN202210507660.3A patent/CN114606270B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109266680A (zh) * | 2018-10-17 | 2019-01-25 | 江苏集萃药康生物科技有限公司 | 一种应用Cas9技术制备CKO/KI动物模型的方法 |
| CN109777837A (zh) * | 2018-12-26 | 2019-05-21 | 首都医科大学 | 一种利用CRISPR/Cas9系统构建致死基因全身性敲除小鼠模型的方法 |
| CN111961685A (zh) * | 2020-08-18 | 2020-11-20 | 江西中医药大学 | CRISPR Cas9条件性基因敲除鼠、建立方法 |
| CN113373178A (zh) * | 2021-08-13 | 2021-09-10 | 上海南方模式生物科技股份有限公司 | 一种tlr8基因人源化动物模型的构建方法及应用 |
| CN114107382A (zh) * | 2021-11-16 | 2022-03-01 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | G3bp1条件性基因敲除小鼠模型 |
Non-Patent Citations (4)
| Title |
|---|
| A conditional knockout resource for the genome–wide study of mouse gene function;William C. Skarnes et al;《Nature》;20110615;第337-342页 * |
| ACCESSION NO. NM_177389，Mus musculus MIA SH3 domain ER export factor 3 (Mia3), mRNA;Lei Y et al;《GenBank》;20220414;FEATURES,ORIGIN * |
| Global defects in collagen secretion in a Mia3/TANGO1 knockout mouse;Deanna G. Wilson et al;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20021001;第277卷(第49期);第935-949页 摘要，结果，材料与方法，图1部分 * |
| 利用CRISPR/Cas9技术将LoxP序列靶向引入小鼠Alk1基因;徐铭 等;《中国临床神经科学》;20151120;第23卷(第06期);第615-623页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114606270A (zh) | 2022-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106047930B (zh) | 一种PS1基因条件性敲除flox大鼠的制备方法 | |
| CN107475300B (zh) | Ifit3-eKO1基因敲除小鼠动物模型的构建方法和应用 | |
| Schmitt et al. | Engineering Xenopus embryos for phenotypic drug discovery screening | |
| CN110551759B (zh) | 一种提高转基因细胞重组效率的组合物及方法 | |
| CN106191113A (zh) | 一种mc3r基因敲除猪的制备方法 | |
| US20200029538A1 (en) | Genome editing method | |
| CN110643636B (zh) | 一种团头鲂MSTNa&b基因敲除方法与应用 | |
| CN110684777B (zh) | 一段分离的核苷酸序列在肌间刺减少的斑马鱼构建中的应用 | |
| WO2018141127A1 (zh) | 一种免疫缺陷大鼠模型的构建方法 | |
| CN113755498A (zh) | 靶向小鼠Ube3a基因的gRNA及构建AS疾病小鼠模型的方法 | |
| CN110438160A (zh) | 一种Cd2ap基因敲除动物的构建方法及应用 | |
| CN111961685A (zh) | CRISPR Cas9条件性基因敲除鼠、建立方法 | |
| CN106148406B (zh) | 猪ApoE基因敲除载体及其构建方法与应用 | |
| Xu et al. | A transgene-free method for rapid and efficient generation of precisely edited pigs without monoclonal selection | |
| WO2020204159A1 (ja) | ノックイン細胞の作製方法 | |
| CN110468132B (zh) | 一种sgRNA及转基因表达载体、表达品系、筛选方法 | |
| CN114606270B (zh) | 一种Mia3条件性基因敲除小鼠模型的构建方法 | |
| CN114592011B (zh) | 一种ptdss2条件性基因敲除小鼠模型的构建方法 | |
| DE112016001619T5 (de) | Verfahren zum herstellen eines nicht-humanen säugetiers oder fisches, das/der jeweils in der lage ist, gameten herzustellen, die ihren ursprung in einem anderen individuum haben | |
| CN105440111B (zh) | 一对转录激活子样效应因子核酸酶及其编码序列与应用 | |
| CN111549070B (zh) | 对x染色体多拷贝基因进行编辑实现动物性别控制的方法 | |
| CN110402893B (zh) | 一种Nrf2基因缺失斑马鱼突变体的制备及其应用 | |
| CN109694885B (zh) | 基于CRISPR/Cas9技术制备PI3Kγ全身敲除模式小鼠方法及其应用和试剂盒 | |
| CN115725590B (zh) | Oser1基因在提升动物生殖力或延缓生殖衰老中的应用和方法 | |
| CN110643605B (zh) | 一种团头鲂MSTNa&b基因敲除的gRNA及其模板 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |